FDA accepts NDA for topical gel formulation for OAB

Article

A new drug application for a topical gel formulation of oxybutynin chloride in the treatment of overactive bladder has been accepted for filing by the FDA, according to Watson Pharmaceuticals, Inc., the manufacturer.

A new drug application for a topical gel formulation of oxybutynin chloride in the treatment of overactive bladder has been accepted for filing by the FDA, according to Watson Pharmaceuticals, Inc., the manufacturer.

The new formulation is a clear, rapid-drying, ethanolic gel designed to deliver consistent oxybutynin concentrations over a 24-hour period in a non-patch transdermal form. By administering oxybutynin through the skin, the treatment avoids first-pass metabolism and the resultant high metabolite levels seen with oral dosing, the company says. A nickel-sized, 1-gram unit dose of oxybutynin gel, applied once daily, delivers about 4 mg of oxybutynin.

The NDA filing is based on data from a phase III, randomized, double-blind, placebo-controlled study involving 789 patients with OAB. In the 12-week study, patients treated with the therapy once daily experienced a highly significant decrease in OAB symptoms versus placebo, including the number of urinary incontinence episodes per day and urinary frequency, and an increase in the average urine volume per void. The gel was well tolerated in the study, and no serious adverse events appeared related to treatment.

Related Videos
Leonardo Kayat Bittencourt, MD, PhD, answers a question during a Zoom video interview
blur image background of corridor in hospital or clinic image | Image Credit @ whyframeshot - stock.adobe.com
Male and female surgeon performing surgery | Image Credit: © Georgii - stock.adobe.com
 Licensed   FILE #:  458906503  Preview Crop  Find Similar  Expand Image DIMENSIONS 8000 x 5333px FILE TYPE JPEG CATEGORY The Environment LICENSE TYPE Standard or Extended A lake in the shape of a recycling sign in the middle of untouched nature | Image Credit: © malp - stock.adobe.com
Dr. Mehmet Asim Bilen in an interview with Urology Times
Anne M. Suskind, MD, MS, FACS, FPMRS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.